To identify innovations that may address multiple disease-driving pathways related to immune-mediated inflammatory diseases, Johnson & Johnson is proud to launch the Pitching Respiratory Innovation QuickFire Challenge. Innovators worldwide are invited to submit ideas to target novel pathways or approaches with the potential to deliver treatments for patients living with Asthma and/or Chronic Obstructive Pulmonary Disease (COPD) with a particular focus on non-type 2 (non-T2) mechanisms.
Selected applicants will have the opportunity to showcase their science to a panel of Johnson & Johnson Innovative Medicine Immunology leaders in a closed-door virtual pitch in late August.*
Despite advances in respiratory science, patients with Asthma and COPD — particularly those whose conditions are driven by non-T2 inflammatory pathways — may have limited or could benefit from more advanced treatment options.1 Research suggests that targeting these alternative pathways could unlock novel therapeutic strategies capable of addressing the unmet needs of these individuals.
At Johnson & Johnson, we are committed to delivering transformational therapies for people living with immune-mediated inflammatory diseases. This challenge reflects our dedication to identifying novel scientific approaches that can help expand treatment options and improve care for patients with Asthma and COPD—particularly those whose needs remain unmet by current therapies.
What we’re looking for
Innovators worldwide are invited to submit ideas to target novel pathways or approaches with the potential to deliver treatments for patients living with Asthma and/or Chronic Obstructive Pulmonary Disease (COPD) with a particular focus on non-type 2 (non-T2) mechanisms.
Special consideration will be given to submissions with proof-of-concept data and preclinical or asset-stage programs with in vitro/in vivo validation.
Research approaches that are not within scope for this challenge include:
Inhaled drug delivery approaches
Cystic fibrosis (genetic defect-targeting) therapies
Antibiotic-based strategies for chronic bronchitis
Alpha-1 antitrypsin deficiency therapies
Drug repurposing
Evaluation Criteria
Potential solutions will be evaluated by a panel of reviewers on their ability to meet the following criteria:
Strategic alignment or relevance to non-T2 inflammatory pathways in Asthma and COPD
Differentiation of asset profile or validated platform for novel target identification
Feasibility of development of the asset
Demonstration of safety and efficacy through clinical or preclinical proof-of-concept data
Identification of key resources and a plan to further the idea
Team expertise and capabilities
Awards:- Selected applicants will have the opportunity to showcase their science to a panel of Johnson & Johnson Innovative Medicine Immunology leaders in a closed-door virtual pitch in late August.
Deadline:- 11-07-2025
